Bio-link Australia Pty. Ltd.

20th July 2017 – Oncology Venture receives option right to execute licence for clinical-stage cancer therapeutic from Novartis.

Oncology Venture, a precision oncology biopharmaceutical company and Bio-Link client, has entered an agreement with pharmaceutical giant Novartis to evaluate the potential of in-licensing an undisclosed, clinical-stage cancer therapeutic. Under the terms of the deal, Oncology Venture receives an option right to execute an exclusive licence to develop and commercialise the small molecule kinase inhibitor, which has previously been explored in multiple therapeutic indications including solid tumours.

Oncology Venture will use its Drug Response Predictor (DRP™) technology to evaluate whether it can validate a companion diagnostic for Novartis’ drug and predict which patients are likely to respond to treatment. Dr Peter Buhl Jensen, CEO of Oncology Venture, is “confident that by using our DRP™ technology to select patients we will raise the chances of success for the molecule in clinical development.” Read the full press release here.